132 related articles for article (PubMed ID: 34414842)
1. Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma.
Alderuccio JP; Kuker RA; Barreto-Coelho P; Martinez BM; Miao F; Kwon D; Beitinjaneh A; Wang TP; Reis IM; Lossos IS; Moskowitz CH
Leuk Lymphoma; 2022 Jan; 63(1):43-53. PubMed ID: 34414842
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
3. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with
Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783
[TBL] [Abstract][Full Text] [Related]
5. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP; Reis IM; Hamadani M; Nachiappan M; Leslom S; Kahl BS; Ai WZ; Radford J; Solh M; Ardeshna KM; Hess BT; Lunning MA; Zinzani PL; Stathis A; Carlo-Stella C; Lossos IS; Caimi PF; Han S; Yang F; Kuker RA; Moskowitz CH
Clin Cancer Res; 2024 Jan; 30(1):139-149. PubMed ID: 37855688
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
7. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
8. Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.
Campiotti L; DE Palma D; Guasti L; Proserpio I; Casagrande S; Schiorlin I; Bolzacchini E; Suter M; Ogliari F; Squizzato A
Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):59-63. PubMed ID: 30781938
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
Cottereau AS; Meignan M; Nioche C; Capobianco N; Clerc J; Chartier L; Vercellino L; Casasnovas O; Thieblemont C; Buvat I
Ann Oncol; 2021 Mar; 32(3):404-411. PubMed ID: 33278600
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.
Song MK; Chung JS; Shin HJ; Lee SM; Lee SE; Lee HS; Lee GW; Kim SJ; Lee SM; Chung DS
Ann Hematol; 2012 May; 91(5):697-703. PubMed ID: 22071570
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma.
Oiwa K; Fujita K; Lee S; Morishita T; Tsujikawa T; Negoro E; Hara T; Tsurumi H; Ueda T; Yamauchi T
Ann Hematol; 2023 May; 102(5):1141-1148. PubMed ID: 36951966
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
14. Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
Mikhaeel NG; Heymans MW; Eertink JJ; de Vet HCW; Boellaard R; Dührsen U; Ceriani L; Schmitz C; Wiegers SE; Hüttmann A; Lugtenburg PJ; Zucca E; Zwezerijnen GJC; Hoekstra OS; Zijlstra JM; Barrington SF
J Clin Oncol; 2022 Jul; 40(21):2352-2360. PubMed ID: 35357901
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the prognostic values of
Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
[TBL] [Abstract][Full Text] [Related]
16. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
[TBL] [Abstract][Full Text] [Related]
17. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
19. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.
Ceriani L; Gritti G; Cascione L; Pirosa MC; Polino A; Ruberto T; Stathis A; Bruno A; Moccia AA; Giovanella L; Hayoz S; Schär S; Dirnhofer S; Rambaldi A; Martinelli G; Mamot C; Zucca E
Blood Adv; 2020 Mar; 4(6):1082-1092. PubMed ID: 32196557
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
